Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Capricor Therap (NQ: CAPR )

5.110 +0.060 (+1.19%)
Streaming Delayed Price Updated: 12:31 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therap

< Previous 1 2 3 Next >
Recap: Capricor Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Capricor Therapeutics's Earnings Outlook
Via Benzinga
Preview: Capricor Therapeutics's Earnings
Via Benzinga
FlexShopper And 3 Other Penny Stocks Insiders Are Buying
The Dow Jones closed higher by around 65 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Turn Lower; Dow Tumbles Over 200 Points
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling over 200 points on Friday. The Dow traded down 0.70% to 33,432.17 while the NASDAQ fell 0.15% to 13,181.22. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Capricor Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview For Capricor Therapeutics
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Crude Oil Down 1% Following PCE Data; Blue Apron Shares Surge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday. The Dow traded up 0.13% to 33,710.74 while the NASDAQ rose 0.99% to 13,331.54. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded up 0.24% to 33,746.70 while the NASDAQ rose 1.22% to 13,362.51. The S&P 500 also rose,... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study
Via Benzinga
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
Capricor Initiates Late-Stage Neuropsychiatric Disorder Study
Capricor Therapeutics (NASDAQ: CAPR) initiated dosing of first patient in HOPE-3, a Phase 3 clinical trial investigating CAP-1002 for treating late-stage Duchenne muscular dystrophy (DMD). 
Via Benzinga
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
7 Undervalued Penny Stocks With Major Upside
Each of these penny stocks has proven momentum throughout 2022 and major upside on top of the returns through the the first quarter. 
Via InvestorPlace
50 Biggest Movers From Yesterday
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in... 
Via Benzinga
Mid-Afternoon Market Update: Dow Drops 150 Points; Capricor Therapeutics Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Monday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 38.3% to $1.66 during Monday's regular session. The current volume of 3.5 million shares is 142.9% of TC... 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) jumped 57.1% to $1.96 following reports regarding potential future investments from AMC CEO, Adam Aron.... 
Via Benzinga
Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial
Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers OncoSec Medical (NASDAQ:ONCS) shares moved upwards by 27.1% to $1.5 during Monday's pre-market session. The company's market cap stands at $59.0 million.... 
Via Benzinga
Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate
In its Q4 FY21 earnings press release, Capricor Therapeutics Inc (NASDAQ: CAPR) said it had halted work on the exosome-based jab due to the "current... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.